Key Takeaways
Lundbeck reported 14% revenue growth in 2024 on the strength of four drugs for CNS disorders.
Rexulti, in particular, is expected to be a continued growth-driver, driven by sales in agitation associated with Alzheimer’s and potentially expansion into PTSD.
Two pivotal trials are enrolling now for bexicaserin, the 5HT2C agonist Lundbeck acquired last year with Longboard Pharmaceuticals.
H
The company’s 2024 financial results released on 5 February showed strong revenue and adjusted earnings growth powered by strategic brands including: Rexulti (brexpiprazole) for depression, schizophrenia and agitation associated with dementia due to Alzheimer’s disease (AADAD); Brintellix/Trintellix (vortioxetine) for major depressive disorder;
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?